Development asset linked to Zealand Pharma in public FDA and regional records.
pharma · Weight management · Short Bowel Syndrome
Zealand Pharma
Zealand Pharma A/S
Zealand Pharma drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Sydmarken 11, Søborg (Copenhagen), 2860, DK HQ
1998 Founded
596 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Sydmarken 11, Søborg (Copenhagen), 2860, DK
- Founded
- 1998
- Employees
- 596
- Programs
- 18
- Drugs
- 20
- Patents
- 0
Zealand Pharma pipeline
Portfolio lens on 20 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zealand Pharma drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
dasiglucagon
Systemic hormonal preparations (H04)Systemic hormonal preparations (H04) compound in Zealand Pharma's portfolio. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
glucagon
Systemic hormonal preparations (H04)US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
Development asset linked to Zealand Pharma in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
panobinostat
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Zealand Pharma's portfolio. Mechanism: Histone deacetylase inhibitor.
- Mechanism
- Histone deacetylase inhibitor
-
pantoprazole
Alimentary tract and metabolism (A02)Alimentary tract and metabolism (A02) compound in Zealand Pharma's portfolio. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
Development asset linked to Zealand Pharma in public FDA and regional records. Mechanism: Sodium channel alpha subunit blocker.
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Zealand Pharma in public FDA and regional records.
-
Development asset linked to Zealand Pharma in public FDA and regional records.